XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.1
STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Feb. 28, 2019
Feb. 28, 2018
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (1,637,717) $ (1,612,101)
Adjustments to reconcile net loss to net cash used in operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 1,081,051 1,218,134
Changes in operating assets and liabilities    
Prepaid expenses 6,959 (28,423)
Retainer   10,000
Accounts payable 59,124 22,289
Accrued liabilities 13,067 70,608
NET CASH USED IN OPERATING ACTIVITIES (477,516) (319,493)
CASH FLOWS FROM FINANCING ACTIVITIES    
Cash contribution recorded 477,718 319,268
NET CASH PROVIDED BY FINANCING ACTIVITIES 477,718 319,268
NET INCREASE (DECREASE) IN CASH 202 (225)
CASH AT BEGINNING OF YEAR 506 731
CASH AT END OF YEAR $ 708 506
Cash Paid During the Year For:    
Interest   $ 31,471